APPLICATIONS OPEN FOR COHORT 2 OF SDA TAP LAB – CATALYST CAMPUS MINI ACCELERATOR
Over an intensive eight-week hybrid program beginning June 9, selected companies will engage in technical workshops, one-on-one mentorship, and direct collaboration with SDA and national defense stakeholders. Programming includes an in-person session from June 17 to June 27 at Catalyst Campus in Colorado Springs, CO.
Advertisement
Companies selected for Cohort 2 will gain:
Access to government and industry subject matter experts
Hands-on support with SDA TAP Lab onboarding
Guidance in shaping product roadmaps to align with real SDA mission needs
A direct path to potential integration with Project Apollo following program completion
The SDA TAP Lab – Catalyst Campus Mini Accelerator fosters a critical pipeline of innovation by enabling early-stage and dual-use companies to mature technologies that directly contribute to space domain awareness and the broader Department of Defense (DoD) mission. The second cohort will focus on engaging companies whose capabilities align with key problem sets currently being addressed by the SDA TAP Lab through Project Apollo. Areas of interest for this cohort include:
SDA TAP Lab Problem 1: Using commercial or public imagery, detect the start of a space launch cycle automatically.
SDA TAP Lab Problem 3: Using seismic data, commercially available cell-phone accelerometer data, or weather data, detect the time and location of foreign space launches automatically.
SDA TAP Lab Problem 7: Using orbital data and/or knowledge of sensors and satellites, develop a sensor search technique that maximizes the probability of reacquiring a satellite or space launch vehicle. The technique must be valid for ground or space based EO, IR, RF, or RADAR sensors.
SDA TAP Lab Problem 9: Using orbital data, develop a specialized technique to process uncorrelated tracks (UCTs) and promote candidate orbits generated from UCTs which may actively manage their optical or radar signatures or otherwise be evading detection, tracking, and identification.
SDA TAP Lab Problem 11: Using orbital data, automatically detect separation events and classify them as either 1) sub-satellite deployment, 2) Debris generating event. Further sub-classify debris generating events, as either: Shedding, Explosion, Impact
SDA TAP Lab Problem 16: Since we assume surprise may come through camouflage, concealment, deception or maneuver (CCDM) we must interrogate targets for evidence of CCDM. Develop techniques to evaluate whether combinations of the following are true of UCT candidate orbits, or satellites in a catalog classified as unknown (UNK), debris (DEB), rocket body (R/B), or an inactive payload:
Object is stable Stability has changed
SDA TAP Lab Problem 20: Generate a radio frequency (RF) pattern of life for individual satellites. This may include typical bandwidth, channel, mode, center frequency, power, encryption, or beam pointing.
Companies interested in applying should review the SDA problem statements and application criteria at: https://spaceforceaccelerato.smapply.io/prog/sda_tap_lab_-_catalyst_campus_mini_accelerator_cohort_2/
Key Dates for Cohort 2:
Applications Close: May 21, 2025
May 21, 2025 Company Onboarding: June 3–6, 2025
June 3–6, 2025 Program Dates: June 9 – August 1, 2025
June 9 – August 1, 2025 In-Person Weeks: June 17 – June 27, 2025
Organizations with innovative space or dual-use technologies aligned with the SDA TAP Lab's mission are highly encouraged to apply.
About Catalyst Campus
The SDA TAP Lab Mini Accelerator is a high-impact program designed to support early-stage companies in rapidly developing and refining technology solutions for Space Domain Awareness (SDA). Over two-month cycles, it provides participants with intensive mentorship, technical workshops, and access to cutting-edge data and computational resources. The program focuses on addressing specific SDA problem statements by fostering collaboration with operators and aligning solutions with real-world needs. The program is headquartered on the Catalyst Campus for Technology and Innovation (CCTI) in Colorado Springs, Colorado. CCTI is a collaborative ecosystem where industry, small business, entrepreneurs, startups, government, academia, and investors intersect with Colorado's aerospace and defense industry to create community, spark innovation, and stimulate business growth.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
50-Day Countdown to the 2025 CIFTIS Starts
BEIJING, July 23, 2025 (GLOBE NEWSWIRE) — The 2025 China International Fair for Trade in Services (CIFTIS) will be held from September 10 to 14 at Shougang Park in Beijing, with a 50-day countdown starting today. As a key global platform for exchange and cooperation in the field of trade in services, the upcoming CIFTIS will continue to deepen international collaboration, gather global insights, and showcase the latest achievements and emerging trends in the sector — injecting fresh momentum into the recovery and growth of the world economy. A Media Snippet accompanying this announcement is available by clicking on this link. Source: CIFTIS
Hamilton Spectator
5 hours ago
- Hamilton Spectator
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of its previously announced non-brokered private placement of units ('Units'), whereby it issued 1,267,123 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$925,000 pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (the 'Offering'). Under the Offering, each Unit consisted of one common share in the capital of the Company ('Common Share') and one common share purchase warrant ('Warrant'). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of US$1.20 for a period of sixty (60) months following the date of issuance provided, however, that if the closing price of the Common Shares on the Nasdaq is greater than US$2.00 for ten (10) or more consecutive trading days, the Warrants will be accelerated and will expire on the 30th business day following the date of such notice. Closing of the Offering was approved by the TSX Venture Exchange ('TSXV'), and the securities issued under the Offering will not be subject to a four-month and one-day statutory hold period. The Company intends to use the proceeds of the Offering as more specifically described in the Offering Document and for gout programs, general corporate and working capital purposes. In connection with the Offering, the Company paid an aggregate of $12,264 in finder's fees and issued, in aggregate, 16,800 finder's warrants. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any applicable state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. persons,' as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The issuance of 8,191 Units to an insider of the Company constitutes a 'related party transaction' as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions ('MI 61-101'). Pursuant to Sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company relied on exemptions from the formal valuation and minority shareholder approval requirements, respectively, as neither the fair market value of the Units nor the consideration for such Units, insofar as it involves the insider, exceeds 25 percent of the Company's market capitalization. In other news, the non-brokered private placement that was announced on May 19, 2025 will not proceed. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at . For more information, please contact: Forward-Looking Statements Statements contained in this news release that are not historical facts are 'forward-looking information' or 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as 'anticipate', 'proposed', 'estimates', 'would', 'expects', 'intends', 'plans', 'may', 'will', and similar expressions, although not all forward-looking information contains these identifying words. More particularly and without limitation, the forward-looking information in this news release includes (i) expectations regarding the Company's current and future financing plans; (ii) expectations concerning the Company's plans and objectives in respect of the Offering's gross proceeds; and (iii) expectations regarding the Company's business plans and operations. Forward-looking information is based on a number of factors and assumptions that have been used to develop such information, but which may prove to be incorrect and are inherently subject to significant business, economic and competitive uncertainties, and contingencies. The material factors and assumptions used in preparing the forward-looking information contained herein include, among others, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and our ability to obtain and maintain intellectual property protection for our product candidates. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the Company's current expectations, assumptions and/or beliefs based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading 'Risk Factors' in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on . Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Hamilton Spectator
5 hours ago
- Hamilton Spectator
Global Uranium Corp. Announces LIFE Offering for up to C$1,500,000
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | FRA: Q3J) (the 'Company') announces a non-brokered private placement financing (the 'Offering') of a Company (each, a 'Unit'), minimum of 6,666,666 units of the Company (each, a 'Unit') up to a maximum of 10,000,000 Units, at a price of C$0.15 per Unit, for gross minimum proceeds of C$1,000,000 and gross maximum proceeds of C$1,500,000. Each Unit shall be comprised of one common share in the capital of the Company (each, a 'Share') and one Share purchase warrant ('Warrant'), with each Warrant entitling the holder to purchase one Share at a price of C$0.20 for a period of 24 months from Closing (as defined herein). Closing of the Offering is anticipated to occur on or about August 11, 2025 ('Closing'), subject to the satisfaction of certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. The net proceeds of the Offering are intended to be used for exploration activities, for general administrative expenditures, and for general working capital purposes. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions ('NI 45-106'), the securities issuable under the Offering will be offered for sale to purchasers resident in all of the provinces of Canada (except Quebec) pursuant to the listed issuer financing exemption under Part 5A.2 of NI 45-106 (the 'LIFE Exemption'). As such, the securities issued to subscribers will not be subject to resale restrictions in accordance with applicable Canadian securities laws. This Offering is not an amendment to, or an extension of, the offering originally announced in the Company's news release dated June 10, 2025. The Company has chosen to discontinue that offering. The offering document originally filed by the Company on June 10, 2025, in connection with such offering document is hereby withdrawn by the Company. There is an offering document dated July 22, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at . The offering document contains further details regarding the Offering, including additional detail regarding the expected use of proceeds therefrom. Prospective investors in the Offering should read this amended and restated offering document before making an investment decision. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any United States state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any available exemption from the registration requirements of the U.S. Securities Act and applicable United States state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. ABOUT GLOBAL URANIUM CORP. Global Uranium Corp. focuses on exploring and developing uranium assets primarily in North America. The Company currently holds key uranium projects: the Wing Lake Property in the Mudjatik Domain of Northern Saskatchewan, Canada; the Northwest Athabasca Joint Venture with Forum Energy Metals Corp. and NexGen Energy Ltd. in the Northwest Athabasca region of Saskatchewan, Canada; the Astro Uranium Project with Cosa Resources Corp in the eastern Athabasca Basin, Saskatchewan; and the Great Divide Basin District Projects, the Gas Hills District Projects, and the Copper Mountain District Projects in Wyoming, USA. ON BEHALF OF THE BOARD OF DIRECTORS Ungad Chadda CEO and Director 587-330-0045 info@ FORWARD-LOOKING STATEMENTS Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the Offering, including the total amount of securities sold to the offering, anticipated proceeds, the expected use of proceeds, satisfaction of conditions to closing, and the closing (including the proposed closing date) of the Offering, if it is to close at all. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including the assumption that the Company will close the Offering on the timeline anticipated, will raise the anticipated amount of gross proceeds from the Offering and will use the proceeds of the Offering as anticipated. Those assumptions and factors are based on information currently available to the Company. Although such statements are based on reasonable assumptions of the Company's management, there can be no assurance that any conclusions or forecasts will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include: the risk that the Offering does not close on the timeline expected, or at all; the risk that the Company raises less than the anticipated amount of gross proceeds from the Offering; the risk that the Company does not use the proceeds from the Offering as currently expected; risks inherent in the exploration and development of mineral deposits, including risks relating to receiving requisite permits and approvals, changes in project parameters or delays as plans continue to be redefined, that mineral exploration is inherently uncertain and that the results of mineral exploration may not be indicative of the actual geology or mineralization of a project; that mineral exploration may be unsuccessful or fail to achieve the results anticipated by the Company; operational risks; regulatory risks, including risks relating to the acquisition of the necessary licenses and permits; financing, capitalization and liquidity risks; title and environmental risks; and risks relating to the failure to receive all requisite regulatory approvals. The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.
